临床研究

双螨皮下免疫治疗时序疗法的3年疗效与安全性评估

  • 李航 ,
  • 杨晓媚 ,
  • 吕雯 ,
  • 陈慧敏 ,
  • 徐睿
展开
  • 1.中山大学附属第一医院耳鼻咽喉科医院,耳鼻咽喉科,(广东 广州 510080 )
    2.中山大学附属第一医院耳鼻咽喉科医院,变态反应科,(广东 广州 510080 )

收稿日期: 2025-09-07

  网络出版日期: 2025-11-13

基金资助

国家自然科学基金项目(82101186);广东省自然科学基金项目(2022A1515012394);广州市基础与应用基础研究专题(青年博士“启航”项目)(2024A04J4630);中山大学附属第一医院“柯麟新星人才”项目(R08036)

Three⁃year evaluation of the efficacy and safety of chronotherapy in dual⁃allergen subcutaneous immunotherapy

  • Hang LI ,
  • Xiaomei YANG ,
  • Wen LYU ,
  • Huimin CHEN ,
  • Rui. XU
Expand
  • *.Department of Otorhinolaryngology,Department of Allergy,Otorhinolaryngology Hospital,the First Affiliated Hospital of Sun Yat?sen University,Guangzhou 510080,Guangdong,China

Received date: 2025-09-07

  Online published: 2025-11-13

摘要

目的 探讨不同给药时间对双螨皮下免疫治疗(SCIT)对过敏性鼻炎(AR)患者的疗效与安全性。 方法 采用回顾性队列研究,纳入39例完成3年标准化双螨SCIT的尘螨过敏AR患者。根据患者自行选择并固定的注射时间,非随机地分为上午组(MD组,8:00—12:00,n = 19)和下午组(AD组,14:00—18:00,n = 20),并进一步按2 h间隔细分亚组。采用视觉模拟量表(VAS)评估治疗前后鼻部与眼部症状,同时记录所有不良反应。 结果 AD组在鼻痒症状的改善上显著优于MD组(中位数差值:-2 vs. 0,U = 118.5,P = 0.04,效应值r = 0.33)。在喷嚏、鼻塞、流涕及总分的改善上,AD组也显示出更优趋势,但差异无统计学意义(P > 0.05)。按2 h间隔细分的亚组中,16:00—18:00亚组症状改善优于8:00—10:00亚组,但差异无统计学意义(P > 0.05)。两组在总不良反应率、局部及全身不良反应率上均差异无统计学意义(P > 0.05),未发生中重度全身反应。 结论 下午(尤其是16:00—18:00)进行双螨SCIT显示出改善鼻部症状的潜力且未增加安全风险。给药时间或为优化SCIT提供新的研究方向。

本文引用格式

李航 , 杨晓媚 , 吕雯 , 陈慧敏 , 徐睿 . 双螨皮下免疫治疗时序疗法的3年疗效与安全性评估[J]. 实用医学杂志, 2025 , 41(21) : 3405 -3411 . DOI: 10.3969/j.issn.1006-5725.2025.21.016

Abstract

Objective To investigate the effects of different administration times on the efficacy and safety of subcutaneous immunotherapy using dual mite extracts in patients with allergic rhinitis (AR). Methods This study was designed as a retrospective cohort analysis. Thirty-nine mite-sensitized AR patients who completed three years of standardized dual-mite subcutaneous immunotherapy (SCIT) were included. Based on self-selected and consistently maintained injection schedules, patients were non-randomly assigned to either a morning dosing group (MD group, 8:00—12:00, n = 19) or an afternoon dosing group (AD group, 14:00—18:00, n = 20), with further subgroup stratification conducted at 2-hour intervals. Nasal and ocular symptoms were evaluated before and after treatment using the visual analog scale (VAS), and all adverse reactions were systematically recorded. Results The AD group exhibited significantly greater improvement in nasal itching compared to the MD group (median difference: -2 vs. 0, U = 118.5, P = 0.04, effect size r = 0.33). The AD group also demonstrated favorable trends toward improved sneezing, nasal congestion, rhinorrhea, and total VAS score, although these differences did not reach statistical significance. In the subgroup analysis by 2-hour intervals, the 16:00—18:00 subgroup showed greater symptom relief than the 8:00—10:00 subgroup, though the difference was not statistically significant. No significant differences were observed between the two groups in the incidence of total, local, or systemic adverse reactions (P > 0.05), and no moderate or severe systemic adverse events occurred. Conclusions This preliminary retrospective analysis indicates that afternoon administration of dual-mite SCIT, particularly between 16:00 and 18:00, may enhance the improvement of nasal symptoms without elevating safety concerns. The timing of SCIT administration could therefore represent a promising avenue for treatment optimization.

参考文献

[1] BOUSQUET J, ANTO J M, BACHERT C, et al. Allergic rhinitis[J]. Nat Rev Dis Primers, 2020, 6(1): 95. doi:10.1038/s41572-020-00227-0
[2] 胡泽功,白燕. 过敏原特异性免疫治疗的研究进展[J]. 实用医学杂志,2025,41(11):1760-1766.
[3] PENAGOS M, DURHAM S R. Duration of allergen immunotherapy for inhalant allergy[J]. Curr Opin Allergy Clin Immunol, 2019, 19(6): 594. doi:10.1097/aci.0000000000000585
[4] CHU D K, WOOD R A, FRENCH S, et al. Oral immunotherapy for peanut allergy (PACE): A systematic review and meta-analysis of efficacy and safety[J]. Lancet, 2019, 393(10187): 2222-2232. doi:10.1016/s0140-6736(19)30420-9
[5] NELSON H S, SOWERS T, PLUNKETT G, et al. The Art of Dosing for Subcutaneous Immunotherapy in North America[J]. J Allergy Clin Immunol Pract, 2024, 12(1): 13-22. doi:10.1016/j.jaip.2023.06.036
[6] SOHN M H. Efficacy and Safety of Subcutaneous Allergen Immunotherapy for Allergic Rhinitis[J]. Allergy Asthma Immunol Res, 2018, 10(1): 1-3. doi:10.4168/aair.2018.10.1.1
[7] CONTOLI M, PORSBJERG C, BUCHS S, et al. Real-world, long-term effectiveness of allergy immunotherapy in allergic rhinitis: Subgroup analyses of the REACT study[J]. J Allergy Clin Immunol, 2023, 152(2): 445-452.e4. doi:10.1016/j.jaci.2023.02.024
[8] BINDER E, HOLOPAINEN E, MALMBERG H, et al. Anamnestic data in allergic rhinitis[J]. Allergy, 1982, 37(6): 389-396. doi:10.1111/j.1398-9995.1982.tb02317.x
[9] SMOLENSKY M H, REINBERG A, LABRECQUE G. Twenty-four hour pattern in symptom intensity of viral and allergic rhinitis: Treatment implications[J]. J Allergy Clin Immunol, 1995, 95(5): 1084-1096. doi:10.1016/s0091-6749(95)70212-1
[10] REINBERG A, GERVAIS P, LEVI F, et al. Circadian and circannual rhythms of allergic rhinitis: An epidemiologic study involving chronobiologic methods[J]. J Allergy Clin Immunol, 1988, 81(1): 51-62. doi:10.1016/0091-6749(88)90220-5
[11] NAHMIAS Y, ANDROULAKIS I P. Circadian Effects of Drug Responses[J]. Annu Rev Biomed Eng, 2021, 23: 203-224. doi:10.1146/annurev-bioeng-082120-034725
[12] TUREK F W. Circadian clocks: Not your grandfather′s clock[J]. Science, 2016, 354(6315): 992-993. doi:10.1126/science.aal2613
[13] DRUZD D, MATVEEVA O, INCE L, et al. Lymphocyte Circadian Clocks Control Lymph Node Trafficking and Adaptive Immune Responses[J]. Immunity, 2017, 46(1): 120-132. doi:10.1016/j.immuni.2016.12.011
[14] BALLESTA A, INNOMINATO P F, DALLMANN R, et al. Systems Chronotherapeutics[J]. Pharmacol Rev, 2017, 69(2): 161-199. doi:10.1124/pr.116.013441
[15] STORMS W W. Pharmacologic approaches to daytime and nighttime symptoms of allergic rhinitis[J]. J Allergy Clin Immunol, 2004, 114(5): S146-S153. doi:10.1016/j.jaci.2004.08.045
[16] SMOLENSKY M H, LEMMER B, REINBERG A E. Chronobiology and chronotherapy of allergic rhinitis and bronchial asthma[J]. Adv Drug Deliv Rev, 2007, 59(9-10): 852-882. doi:10.1016/j.addr.2007.08.016
[17] IGARASHI S, SUZUKI K, NAKAMURA Y, et al. The Efficacy of Sublingual Immunotherapy for Allergic Rhinitis May Vary with the Time of Day[J]. Int Arch Allergy Immunol, 2016, 171(2): 111-118. doi:10.1159/000450954
[18] LIAO F, CHEN S, WANG L, et al. Morning Versus Evening Dosing of Sublingual Immunotherapy in Allergic Asthma: A Prospective Study[J]. Front Pediatr, 2022, 10: 892572. doi:10.3389/fped.2022.892572
[19] LI H, YANG X, WEN Y, et al. Three‐Year Longitudinal Evaluation of Timing Effects on Subcutaneous Immunotherapy Efficacy and Safety in Allergic Rhinitis[J]. Clin Exp Allergy, 2025: cea.70075. doi:10.1111/cea.70075
[20] LóPEZ-SANZ C, JIMéNEZ-SAIZ R, ESTEBAN V, et al. Mast Cell Desensitization in Allergen Immunotherapy[J]. Front Allergy, 2022, 3: 898494. doi:10.3389/falgy.2022.898494
[21] COX L, LARENAS-LINNEMANN D, LOCKEY R F, et al. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System[J]. J Allergy Clin Immunol, 2010, 125(3): 569-574.e7. doi:10.1016/j.jaci.2009.10.060
[22] FREW A J. Allergen immunotherapy[J]. J Allergy Clin Immunol, 2010, 125(2): S306-S313. doi:10.1016/j.jaci.2009.10.064
[23] WANG L, WANG C, LOU H, et al. Antihistamine premedication improves safety and efficacy of allergen immunotherapy[J/OL]. Ann Allergy Asthma Immunol, 2021, 127(3): 363-371.e1. doi:10.1016/j.anai.2021.05.023
[24] HERMIDA R C, AYALA D E, SMOLENSKY M H, et al. Chronotherapy improves blood pressure control and reduces vascular risk in CKD[J]. Nat Rev Nephrol, 2013, 9(6): 358-368. doi:10.1038/nrneph.2013.79
[25] SHAMJI M H, LJ?RRING C, FRANCIS J N, et al. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy.[J]. Allergy, 2012, 67(2): 217-226. doi:10.1111/j.1398-9995.2011.02745.x
[26] NAKAO A. Circadian Regulation of the Biology of Allergic Disease: Clock Disruption Can Promote Allergy[J]. Front Immunol, 2020, 11: 1237. doi:10.3389/fimmu.2020.01237
[27] LIN Y, HE L, CAI Y, et al. The role of circadian clock in regulating cell functions: Implications for diseases[J]. MedComm (2020), 2024, 5(3): e504. doi:10.1002/mco2.504
[28] FIDAN V, ALP H H, GOZELER M, et al. Variance of melatonin and cortisol rhythm in patients with allergic rhinitis[J]. Am J Otolaryngol, 2013, 34(5): 416-419. doi:10.1016/j.amjoto.2013.03.004
[29] ANDO N, NAKAMURA Y, ISHIMARU K, et al. Allergen-specific basophil reactivity exhibits daily variations in seasonal allergic rhinitis[J]. Allergy, 2015, 70(3): 319-322. doi:10.1111/all.12552
[30] LONG J E, DRAYSON M T, TAYLOR A E, et al. Morning vaccination enhances antibody response over afternoon vaccination: A cluster-randomised trial[J]. Vaccine, 2016, 34(24): 2679-2685. doi:10.1016/j.vaccine.2016.04.032
[31] ZHANG H, LIU Y, LIU D, et al. Time of day influences immune response to an inactivated vaccine against SARS-CoV-2[J]. Cell Res, 2021, 31(11): 1215-1217. doi:10.1038/s41422-021-00541-6
文章导航

/